History

Afamelanotide traces to the labs of Mac E. Hadley and Victor J. Hruby at the University of Arizona in the early 1980s, where the analog [Nle⁴,D-Phe⁷]-α-MSH ("Melanotan") was characterized as far more potent and longer-acting than native α-MSH in amphibian skin assays; the original goal was photoprotective tanning to cut skin-cancer risk. The technology was licensed to Australia's Epitan, renamed Clinuvel Pharmaceuticals in 2006, which developed a slow-release implant. The EU granted marketing authorisation on 22 December 2014, pivotal trials were published in 2015, and the FDA approved it on 8 October 2019.

Afamelanotide is one of the few compounds in the broad “melanotan” family that is an actual approved medicine rather than a gray-market product. Sold as Scenesse, it is a clinician-implanted drug for a rare inherited light-sensitivity disease. That distinction matters: most of what people read about “melanotan” online concerns an unapproved injectable tanning peptide (Melanotan-2), which is a different molecule with a different safety profile. This profile covers the approved drug, what it is genuinely backed by, and where the evidence is thinner than the headlines suggest.

What it is

Afamelanotide is a synthetic tridecapeptide — a chain of 13 amino acids — built as an analog of the body’s natural α-melanocyte-stimulating hormone (α-MSH), a member of the melanocortin family. Its sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. It differs from native α-MSH at two positions: methionine-4 is swapped for norleucine, and L-phenylalanine-7 is swapped for D-phenylalanine. Those two changes make the molecule resistant to enzymatic breakdown and slow its release from the receptor, giving it the “ultralong” activity its developers described.

Mechanistically, afamelanotide is an agonist at the melanocortin-1 receptor (MC1R) on the pigment-producing melanocytes of the skin, with weaker activity at other melanocortin receptors. Activating MC1R raises cAMP inside the cell, which through a signaling cascade involving PKA, CREB and the transcription factor MITF ramps up the pigment-making enzymes (tyrosinase and related proteins). The net result is increased synthesis of eumelanin — the brown-black, photoprotective pigment — independent of any UV exposure. A frequently repeated claim that these analogs are roughly 1,000 times more potent than native α-MSH appears in secondary sources; the original developers described them as far more potent in early bioassays, but the precise multiplier should be treated as an approximate, second-hand figure rather than a verified measurement.

The claims

There is only one approved claim. Afamelanotide is authorised to increase pain-free light exposure and prevent phototoxic reactions in adults with confirmed erythropoietic protoporphyria (EPP), a rare genetic disorder in which sunlight triggers severe burning skin pain. By raising baseline eumelanin, the drug is meant to give these patients more tolerable time outdoors.

Beyond EPP, afamelanotide has been investigated — but not approved — for vitiligo (as an add-on to narrowband UV-B phototherapy), polymorphous light eruption, solar urticaria and other photosensitivity conditions. Most of these programs are small or unpublished.

Separately, and importantly, the cosmetic “tanning” claims that dominate online discussion of “melanotan” attach mostly to Melanotan-2, not to pharmaceutical afamelanotide. Those products are unapproved and illegal to sell as medicines.

The evidence

For its one approved use, the foundation is two phase 3 randomized, double-blind, placebo-controlled trials published together in the New England Journal of Medicine in 2015. One was run in Europe (74 patients) and one in the United States (94 patients), using a 16 mg subcutaneous implant given every 60 days. The primary endpoint in both was the number of hours of pain-free direct sun exposure that patients logged themselves.

Both trials favored the drug. In the European trial, median pain-free sun time was 6.0 hours versus 0.8 hours for placebo (P=0.005); in the US trial, 69.4 hours versus 40.8 hours (P=0.04). Phototoxic reactions were significantly reduced in the European trial (77 versus 146, P=0.04) but not in the US trial. Quality-of-life scores improved significantly in the US trial (day-180 change 51.1 versus 36.8, P=0.02) but the European difference did not reach significance (day-270 score 79.7 versus 67.2, P=0.06).

Supportive real-world data exist. A single-center Dutch cohort of 117 patients (JAMA Dermatology, 2020) reported about 6.1 more hours per week spent outside and a 14% quality-of-life improvement (both P<0.001), though the number and duration of reactions did not change significantly. A two-center observational study of 115 patients followed for up to eight years (British Journal of Dermatology, 2015) reported quality-of-life scores rising from 31% to 74% of maximum on treatment. For vitiligo, one randomized multicenter trial (JAMA Dermatology, 2015) found afamelanotide plus narrowband UV-B gave somewhat more repigmentation than UV-B alone (48.6% versus 33.3% at day 168), with faster response in darker-skinned patients — but the trial was small and adjunctive, not approval-grade.

This is more and better evidence than most peptides in this space have, which is why the EPP indication earns a “Preliminary human” grade rather than something weaker. But it falls short of an unqualified “Strong human” rating for several honest reasons. The two pivotal trials used different time windows and produced sharply different effect sizes. The primary endpoint was patient-logged, behavior-dependent sun time, which is open to bias even in a blinded design. The reduction in phototoxic reactions was inconsistent between the two trials, and the European quality-of-life result was not significant. Above all, essentially every efficacy dataset is sponsored by or financially tied to the manufacturer, Clinuvel. The evidence is genuine and regulator-vetted, but it is single-sponsor, modest in effect, and fragile at the endpoint level. For tanning and all non-EPP uses, there are no adequate outcome trials, and the grade falls to theoretical or no credible evidence.

Safety and side effects

In the controlled trials, side effects of pharmaceutical afamelanotide were generally mild to moderate, and there were no treatment-related deaths. The approved label lists implant-site reactions (including implant-site discoloration in roughly 10% of patients), nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevi (moles), respiratory tract infection and skin irritation among the more common adverse reactions. Long-term cohorts have reported good tolerability.

Because the drug stimulates melanocytes, periodic skin and mole surveillance is advised. The approved-drug data have not demonstrated an increased melanoma rate, but there are no adequately powered long-term cancer-outcome studies, so this theoretical concern is not fully resolved.

A separate and more alarming safety picture belongs to the gray-market drug Melanotan-2, which should not be conflated with afamelanotide. The published harms from Melanotan-2 are mostly case reports, including darkening and enlargement of moles, dysplastic nevi, and melanoma temporally associated with use — for example, a documented case in a teenager with a familial mole-and-melanoma syndrome who combined Melanotan-2 with tanning beds. There are also risks from non-sterile or counterfeit product. The true incidence of any of these is unknown.

Legal and regulatory status

Afamelanotide is a prescription orphan drug. The European Commission granted marketing authorisation on 22 December 2014, “under exceptional circumstances,” making it the first approved therapy for EPP. The FDA approved it on 8 October 2019 (NDA 210797, sponsor Clinuvel) as a 16 mg subcutaneous implant, placed only by a trained healthcare professional under restricted distribution. It is not a self-administered injection.

Melanotan-2, by contrast, has no marketing authorisation anywhere. Australia’s Therapeutic Goods Administration states that it is not approved, that its development was halted over safety concerns, and that advertising or supplying it is illegal, citing melanoma risk and systemic effects such as nausea, flushing and prolonged erections. UK regulators similarly treat “melanotan” tanning products as unlicensed medicines.

In sport, melanocortin and α-MSH analogs are widely regarded as prohibited substances, but anyone who needs a definitive answer should check the current WADA Prohibited List directly rather than rely on second-hand claims about a specific category.

Bottom line

Afamelanotide is the rare melanotan-family compound that is a real, approved medicine — but only for one rare disease, erythropoietic protoporphyria, and only as a clinician-placed implant. For that narrow use it is backed by two randomized placebo-controlled trials plus observational cohorts, which is a stronger record than most peptides can claim. The honest caveats are that the effect is modest, the endpoints are fragile and patient-reported, the results diverged between trials, and nearly all the data come from a single sponsor. It is not a tanning shortcut, and it is emphatically not the same thing as the unapproved, illegal Melanotan-2 sold online. If you have seen “melanotan” marketed for cosmetic tanning, that is a different and unproven product carrying real, documented harms.

Afamelanotide (Melanotan-1): An Approved Orphan Drug With Modest, Single-Sponsor Evidence